Bronte Capital Management’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Bronte Capital Management’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-154,878	Closed	-$596K	–	36
2023 Q2	$596K	Sell	154,878 -2,577	-2%	-$9.46K	0.06%	32
2023 Q1	$476K	Sell	157,455 -1,950	-1%	-$6.74K	0.06%	30
2022 Q4	$327K	Sell	159,405 -4,142	-3%	-$12.6K	0.04%	27
2022 Q3	$566K	Hold	163,547	–	–	0.07%	28
2022 Q2	$689K	Buy	163,547 +323	+0.2%	+$763	0.08%	32
2022 Q1	$496K	Buy	163,224 +6,008	+4%	+$23K	0.04%	31
2021 Q4	$731K	Sell	157,216 -2,246	-1%	-$15.5K	0.05%	29
2021 Q3	$1.23M	Hold	159,462	–	–	0.09%	27
2021 Q2	$1.37M	Buy	+159,462	New	+$1.41M	0.1%	21

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

Bronte Capital Management's DBTX Position: Q3 2023 in Review

Bronte Capital Management sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 154,878 shares — an estimated $596K sold.

Bronte Capital Management first reported a position in DBTX in Q2 2021 and held it in 9 quarters. The position peaked at $1.37M in Q2 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Bronte Capital Management reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bronte Capital Management sold 154,878 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $596K.
Bronte Capital Management first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Bronte Capital Management's Decibel Therapeutics, Inc. Common Stock position peaked at $1.37M in Q2 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bronte Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.